Cargando…
Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
SIMPLE SUMMARY: Pancreatic ductal adenocarcinoma (PDAC) is one of the tumors with the highest mortality, for which survival has hardly changed in the last 40 years. This high mortality is due to the lack of tests that would allow an early diagnosis and the fact that current treatments are not very e...
Autores principales: | Heredia-Soto, Victoria, Rodríguez-Salas, Nuria, Feliu, Jaime |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074327/ https://www.ncbi.nlm.nih.gov/pubmed/33924143 http://dx.doi.org/10.3390/cancers13081986 |
Ejemplares similares
-
Liquid biopsies, are we ready for prime time?
por: Normanno, Nicola, et al.
Publicado: (2023) -
Liquid biopsy genotyping in lung cancer: ready for clinical utility?
por: Huang, Wei-Lun, et al.
Publicado: (2017) -
Liquid Biopsies in Sarcoma Clinical Practice: Where Do We Stand?
por: van der Laan, Pia, et al.
Publicado: (2021) -
The Significance of Liquid Biopsy in Pancreatic Cancer
por: Qi, Zi-Hao, et al.
Publicado: (2018) -
Liquid biopsy approach to pancreatic cancer
por: Perales, Sonia, et al.
Publicado: (2021)